CD4 and lymphoma: Since RMD-related toxicities have been observed at doses used for the clinical treatment of hematologic malignancies [31], [32], we tested whether RMD can activate latent HIV in patient-derived CD4 T cells at concentrations below its clinical exposure achieved with the dose of 14 mg/m2 used for the treatment of lymphomas [33].